News & Updates

The investigational oral small-molecule glucagon-like peptide-1 receptor agonist (GLP-1 RA) elecoglipron yields meaningful weight reductions with a safety profile consistent with the drug class, according to a phase 2 dose-ranging study.

The V114-032 trial, presented at ESPID 2026, shows that administering the 15-valent pneumococcal conjugate vaccine (PCV15) reduces the incidence of first vaccine-type acute otitis media (VT-AOM) among healthy children.

Topical application of chlorhexidine 1% proves effective at reducing bacterial load in both mothers and neonates, according to the results of a randomized controlled trial.

Oral supplementation with probiotics containing Clostridium species may protect against the recurrence of spontaneous preterm delivery in high-risk pregnant women, according to a prospective, single-arm, trial conducted in Japan.

Complex interactions between glutamatergic, opioidergic, and GABAergic systems modulate the antidepressant effects of ketamine on cerebral blood flow (CBF) in patients with major depressive disorder (MDD), suggests a recent study.

Real-life use of letermovir in paediatric recipients of haematopoietic stem cell transplant (HSCT) is generally safe and prevents the development of cytomegalovirus (CMV) disease, as shown in a study presented at ESPID 2026.

A recent Delphi-based expert consensus has released guidelines on preventing relapse after a successful electroconvulsive therapy (ECT) for patients with major depressive disorder (MDD).

Treatment with a once-weekly injectable petrelintide, a novel human amylin analogue, yields up to 10.7 percent weight loss through week 42 in adults with obesity or overweight, according to the phase II ZUPREME-1 trial presented at ADA 2026.

In the treatment of scabies infection in children up to 2 years of age, age-based ivermectin dosing yields high response rates and is well-tolerated, according to the open-label phase 2 ITCHY 2 study.